Human anti-chimeric antibody

The human anti-chimeric antibody (HACA) can develop in patients undergoing autoimmune disease therapy with the drug infliximab. This drug can cause the patient to develop antibodies to the medicine itself, which are termed HACAs.[1][2]

The incidence of developing these antibodies is highest in patients receiving intermittent therapy with infliximab, and lowest in patient receiving continuous therapy and concomitant immunosuppressive therapy.

There is evidence that the presence of these antibodies causes a decrease in efficacy of infliximab and increased risk of infusion reactions.[3]

References

  1. ^ Lunardon, L.; Payne, A. S. (April 26, 2012). "Inhibitory human anti-chimeric antibodies to rituximab in a pemphigus patient". Allergy Clin Immunol. 130 (3): 800–803. doi:10.1016/j.jaci.2012.03.022. PMC 3412073. PMID 22541247.
  2. ^ Stevens, Misty W; Henry, Ralph L; Owens, S. Michael; Schutz, Ralph; Gentry, W.Brooks (2014). "First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers". mAbs. 6 (6): 1649–1656. doi:10.4161/19420862.2014.976431. PMC 4623385. PMID 25484042.
  3. ^ Moritoki, Yuki (November 1, 2018). "Anti-drug Antibodies Against a Novel Humanized Anti-CD20 Antibody Impair Its Therapeutic Effect on Primary Biliary Cholangitis in Human CD20- and FcγR-Expressing Mice". Front. Immunol. 9 2534. doi:10.3389/fimmu.2018.02534. PMC 6224429. PMID 30450101.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.